Clinical Trials · NCT00427349
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Enrollment
- 46
- Start date
- Nov 2008
- Locations
- 112 sites, United States
- Primary endpoint
- Four-month Progression-free Survival Rate